Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...
Gedatolisib targets HR+/HER2-, PIK3CA wild-type advanced breast cancer, with a PDUFA goal date of July 17, 2026. The drug's multi-target approach inhibits all four class 1 PI3K isoforms, mTORC1, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results